{"id":"W2139142789","doi":"10.1093/annonc/mdm592","title":"A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer","year":2008,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"ca_institutions":"Eli Lilly (Canada); Alberta Cancer Foundation","funders":"U.S. Food and Drug Administration","keywords":"Pemetrexed; Medicine; Hazard ratio; Lung cancer; Internal medicine; Interim analysis; Confidence interval; Oncology; Chemotherapy; Toxicity; Randomized controlled trial; Surgery; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001873932,0.001825473,0.004109434,0.0004439206,0.0005293344,0.001277926,0.001532771,0.002046539,0.01041911],"category_scores_gemma":[0.001966237,0.000807017,0.002338612,0.0005678285,0.001548329,0.001562538,0.0005956409,0.005222102,0.001412252],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001345074,"about_ca_system_score_gemma":0.001489286,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001304148,"about_ca_topic_score_gemma":0.002724566,"domain_scores_codex":[0.9992483,0.0003865887,0.00004160999,0.0001700886,0.00003963734,0.0001136878],"domain_scores_gemma":[0.9986374,0.0004772697,0.0002054996,0.000133835,0.00006602402,0.0004799007],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9885649,0.004102056,0.000233928,0.0001548963,0.0005686719,0.00001279395,0.0000194143,0.000238858,0.001076619,0.00006743998,0.0004603176,0.004500026],"study_design_scores_gemma":[0.9736061,0.02493799,0.0005539707,0.000008941865,0.00025957,0.00001350148,0.000009976181,0.0001651557,0.0001316759,0.00006859384,0.0002389666,0.000005640564],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854112,0.002971474,0.000902741,0.001634502,0.001066354,0.003300691,0.002075858,0.0001391204,0.002498081],"genre_scores_gemma":[0.983643,0.001793064,0.002390575,0.001921893,0.000576242,0.003713159,0.002370977,0.00004515297,0.003545942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01041911,"threshold_uncertainty_score":0.03485537,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05161190808332462,"score_gpt":0.4126153450498675,"score_spread":0.3610034369665429,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}